Urothelial Carcinoma Bladder Clinical Trial
Official title:
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Verified date | June 2024 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in various quality of life metrics, including sexual health, cognitive decline and depression. Furthermore, removal of ovaries has been associated with increased cardiovascular events, metabolic acidosis, osteoporosis and bone fractures. In premenopausal women, the removal of the ovaries is associated with increased all-cause mortality. From an oncologic standpoint, multi institutional retrospective reviews have demonstrated certain pre-operative radiographic and cystoscopic risk factors that are associated with bladder cancer involvement of female reproductive organs. The absence of these unfavorable risk factors may provide an opportunity to spare women from undergoing unnecessary reproductive organ removal during RC. In doing so, this may eliminate the associated sequelae of removing these additional organs while also providing acceptable oncologic care. The investigators thus propose a decision tool to stratify women undergoing radical cystectomy as favorable and unfavorable for reproductive organ sparing radical cystectomy. This decision tool classification will be used to decide which patients will undergo reproductive organ sparing radical cystectomy versus radical cystectomy in this study.
Status | Recruiting |
Enrollment | 147 |
Est. completion date | March 2028 |
Est. primary completion date | March 2027 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Female = eighteen years of age - Histologically proven diagnosis of urothelial carcinoma of the bladder, including variant histology - Surgical candidate for radical cystectomy - Be able to undergo pelvic MRI. Minimum standards for MRI imaging will include the following: - MRI of the pelvis on 1.5T or higher strength magnet. - T2 weighted imaging in multiple planes. - T1 weighted imaging pre and post contrast administration (unless contrast is contraindicated by allergy or renal insufficiency) - Cystoscopic evaluation completed by urologist within 120 days prior to surgery (ROS-RC or RC) - Staging imaging within 90 days prior to surgery (ROS-RC or RC). If receiving neoadjuvant therapy prior to surgery (ROS-RC or RC), repeat staging imaging must be completed after the neoadjuvant therapy is completed, or no longer tolerated by the patient. - Staging imaging must include MRI of the pelvis within 90 days of surgery (ROS-RC or RC) - Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures. - Presence of at least one or more ancillary organs. Ancillary organs defined as anterior vagina, uterus, fallopian tubes (only 1 tube present will be considered at physician discretion), and ovaries. - ECOG Performance Status of 0-2 Exclusion Criteria: - Patients with regional or distant metastatic disease - Non-urothelial bladder cancer. - Not a surgical candidate for radical cystectomy - Unable to have MRI of pelvis that meets the minimum standards in the inclusion criteria above. - Subjects of childbearing potential (SOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy during study intervention and for at least 12 weeks after the study intervention. - Patients with other known active malignancies which may confound the recurrence rates - Patients with known germline mutations in DNA damage repair genes (BRCA1/BRCA 2) - Prisoners or subjects who are involuntarily incarcerated. - Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. - Subjects demonstrating an inability to comply with the study and/or follow-up procedures. - Subjects who are confirmed to be pregnant or breastfeeding. - History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for complications, in the opinion of the treating physician. - Administration of a vaccine containing live virus within 30 days prior to the study intervention. Note: Most flu vaccines are killed viruses, with the exception of the intra-nasal vainer (Flu-Mist) which is an attenuated live virus and therefore prohibited for 30 days prior to first dose. Non-live versions of the COVID vaccine are allowed. |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive margin rate | Determine the positive margin status rate (based on the surgical pathology report) for the favorable cohort who successfully undergo reproductive organ sparing radical cystectomy | 120 days | |
Secondary | Sexual function | Evaluate sexual function as measured by the Female Sexual Function Index (FSFI). The FSFI consists of 19 questions measuring female sexual function across six domains, including desire (2 items), arousal (4 items), lubrication (4 items), orgasm (3 items), satisfaction (3 items), and pain (3 items). Each response is assigned a score of either 0 to 5 or 1 to 5, with a higher score meaning a greater level of sexual functioning. The scores are summed to produce a composite score ranging from 4 to 36, with a higher score meaning better sexual functioning. | 15 months | |
Secondary | Quality of life | Evaluate quality of life as measured by the FACT-G questionnaire. The FACT-G measures various aspects of physical, social, emotional, and functional well-being over the past 7 days on a scale of 0-4 (with 0 meaning "Not at all" and 4 meaning "Very much"). | 15 months | |
Secondary | Local recurrence | Determine the local recurrence rate. | 12 months | |
Secondary | Distant recurrence | Determine the distant recurrence rate. | 12 months | |
Secondary | Incidence rate of adjacent pelvic organ involvement | Determine the incidence of adjacent pelvic organ involvement in women undergoing radical cystectomy deemed "unfavorable" based on the decision tool. | 12 months | |
Secondary | Prediction of extravesicular disease | Evaluate the ability of staging MRI of the pelvis to predict extravesicular disease. | 15 months | |
Secondary | Prediction of adjacent pelvic organ involvement | Evaluate the ability of staging MRI of the pelvis to predict adjacent pelvic organ involvement | 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03606174 -
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT05839119 -
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
|
Phase 1 | |
Completed |
NCT03558503 -
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT05136898 -
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
|
Phase 3 | |
Withdrawn |
NCT06090318 -
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
|
Phase 1/Phase 2 | |
Recruiting |
NCT03185468 -
Intervention of Bladder Cancer by CAR-T
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05243550 -
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05312671 -
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT02951325 -
Bladder Cancer Adjuvant Radiotherapy Trial
|
N/A | |
Recruiting |
NCT05375903 -
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1 | |
Recruiting |
NCT05401279 -
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04386746 -
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05656235 -
Renal Retention in High Grade Upper Tract Urothelial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06331299 -
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Not yet recruiting |
NCT05037279 -
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
|
Phase 3 | |
Terminated |
NCT04688931 -
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05241340 -
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05077709 -
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
|
Phase 2 | |
Completed |
NCT04200963 -
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
|
Phase 1 | |
Recruiting |
NCT04770974 -
Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic
|